NR4A1 and bone metastasis: Specifically, the risk of bone metastasis in TNBC patients is about 2–3 times higher than in hormone receptor positive patients, and the metabolic activity of metastatic lesions is higher, which is manifested as higher SUVmax values in our PET/CT imaging.